SPECIAL REPORT
Executives at Three Companies Cash Out Tens of Millions in Stock
Insider sales at Cabot, Brinker International and Synopsys each topped $5 million in disclosures filed around the same period.
Executive takeaway
Cabot Corp CEO Sean Keohane sold $11.4 million in stock, Brinker International director DePinto sold $5.76 million, and Synopsys executive chair Aart de Geus sold $11.1 million, according to separate disclosures.
A cluster of large insider stock sales surfaced across unrelated sectors. Cabot Corp's president and CEO, Sean Keohane, sold $11.4 million in shares. Brinker International director DePinto sold $5.76 million in stock. Synopsys executive chair Aart de Geus sold $11.1 million in shares. Each sale was disclosed separately and the companies operate in different industries: specialty chemicals, restaurants and semiconductor design software.
Insider sales of this size are routine and do not necessarily signal a view on the company's prospects; many executives sell on preset trading plans to diversify holdings or cover tax obligations. Still, the concentration of eight-figure sales in a single reporting window is notable simply for its size.
None of the filings referenced in these disclosures indicate whether the sales were made under 10b5-1 trading plans, which would suggest they were scheduled in advance rather than tied to any recent company-specific news.
What would change this view
If subsequent SEC filings show these sales were not made under pre-arranged 10b5-1 plans, or if any of the three companies report a material earnings miss in their next quarterly results.
Wire sources cited
- Investing.com — All NewsSynopsys executive chair Aart de Geus sells $11.1m in stockExternal ↗
- Investing.com — All NewsBrinker International director DePinto sells $5.76m in sharesExternal ↗
- Investing.com — All NewsCabot Corp president and CEO Sean Keohane sells $11.4 million in stockExternal ↗
Produced automatically by the INDY NEWS Desk from the public wire sources cited above, and checked against them before publication. Market commentary, not investment advice.